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Munanairi et al. show that the kappa
opioid receptor (KOR) agonists inhibit
nonhistaminergic itch transmission by
attenuating the function of the gastrin-
releasing peptide receptor (GRPR), an
itch receptor in the spinal cord. KOR
activation causes the translocation of
PKCd from plasma to membrane, which
phosphorylates GRPR to dampen itch
transmission.
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Chronic itch or pruritus is a debilitating disorder that
is refractory to conventional anti-histamine treat-
ment. Kappa opioid receptor (KOR) agonists have
been used to treat chronic itch, but the underlying
mechanism remains elusive. Here, we find that KOR
and gastrin-releasing peptide receptor (GRPR) over-
lap in the spinal cord, and KOR activation attenuated
GRPR-mediated histamine-independent acute and
chronic itch in mice. Notably, canonical KOR-medi-
ated Gai signaling is not required for desensitizing
GRPR function. In vivo and in vitro studies suggest
that KOR activation results in the translocation of
Ca2+-independent protein kinase C (PKC)d from the
cytosol to the plasmamembrane, which in turn phos-
phorylates and inhibits GRPR activity. A blockade of
phospholipase C (PLC) in HEK293 cells prevented
KOR-agonist-induced PKCd translocation and
GRPR phosphorylation, suggesting a role of PLC
signaling in KOR-mediated GRPR desensitization.
These data suggest that a KOR-PLC-PKCd-GRPR
signaling pathway in the spinal cord may underlie
KOR-agonists-induced anti-pruritus therapies.866 Cell Reports 23, 866–877, April 17, 2018 ª 2018 The Authors.
This is an open access article under the CC BY-NC-ND license (http://INTRODUCTION
Chronic itch or pruritus may arise from dysfunction of skin, im-
mune, nervous system, or internal organ metabolism, such as
liver and kidney diseases (Ikoma et al., 2006; Paus et al.,
2006). Despite recent progress in identifying signaling molecules
as potential targets for anti-pruritus therapies (Bautista et al.,
2014; Liu and Ji, 2013), much less is known about the central tar-
gets for itch (Barry et al., 2018; Bautista et al., 2014). The mu and
kappa opioid receptor systems appear to have opposing roles in
a wide range of physiological processes (Pan, 1998), including
itch transmission (Ballantyne et al., 1988). Most opioids are pru-
ritogens, and morphine-induced pruritus could be a serious un-
wanted effect of epidural analgesia (Ballantyne et al., 1988;
Reich and Szepietowski, 2010). On the other hand, the inhibitory
effect of kappa opioid receptor (KOR) agonists, e.g., butorphanol
or nalfurafine (TRK-820), on a wide range of itch behaviors has
made them attractive drug candidates for treating patients with
uremic, cholestatic, and opioid-induced pruritus (Cowan et al.,
2015; Kumagai et al., 2010; Lawhorn et al., 1991; Phan et al.,
2012; Togashi et al., 2002; Wikstro¨m et al., 2005). KOR-
agonist-based anti-pruritic therapies, however, may have
unwanted side effects, such as insomnia, somnolence, and con-
stipation (Land et al., 2008; Phan et al., 2012). Despite a potential
for KOR agonists in anti-itch application, the underlying mecha-
nisms remain poorly understood.creativecommons.org/licenses/by-nc-nd/4.0/).
Gastrin-releasing peptide receptor (GRPR) is primarily
required for relaying nonhistaminergic itch in the spinal cord
(Akiyama et al., 2013; Barry et al., 2018; Liu et al., 2011; Shira-
tori-Hayashi et al., 2015; Sun and Chen, 2007; Sun et al.,
2009). Its endogenous ligand, gastrin-releasing peptide (GRP),
is expressed in a subset of dorsal root ganglion (DRG) neurons,
which also overlaps with TRPV1 and substance P (SP) (Barry
et al., 2016; Takanami et al., 2014; Zhao et al., 2013). GRP in
serum, sensory neurons, and GRPR in the spinal cord of mice,
monkeys, and humans with chronic itch were upregulated
(Choi et al., 2016; Kagami et al., 2013; Lou et al., 2017; Nattkem-
per et al., 2013; Tirado-Sa´nchez et al., 2015; Tominaga et al.,
2009; Zhao et al., 2013). A blockade of GRPR or GRP markedly
diminishes long-lasting itch in various types of mouse models
(Lagerstro¨m et al., 2010; Shiratori-Hayashi et al., 2015; Zhao
et al., 2013). These studies raise the question of whether KOR
may inhibit itch in part by blocking GRPR function. Consistent
with this possibility, studies have shown that spinal KOR activa-
tion inhibits GRP-induced scratching (GIS) (Kardon et al., 2014;
Lee and Ko, 2015) and morphine-induced scratching (MIS) (Ko
et al., 2003; Sakakihara et al., 2016).
In this study, we investigated whether spinal KOR activation
attenuates itch transmission by blocking GRPR signaling in
mice. Using several complementary approaches, we have
demonstrated that KOR activation inhibits GRPR signaling via
a Ca2+-independent phospholipase C (PLC)-protein kinase C
(PKC)d pathway. Our studies may help design spinal KOR-
GRPR cross-signaling-based therapeutic strategies to alleviate
chronic itch.
RESULTS
Spinal KOR Activation Inhibits Nonhistaminergic Itch
To determine the effect of spinal activation of KOR on itch,
scratching behavior was quantified in C57BL/6J mice after intra-
thecal (i.t.) injection of U-50,488, a selective KOR agonist (Simo-
nin et al., 1998). Consistent with a previous study (Inan and
Cowan, 2004), U-50,488 significantly attenuated scratching
behavior induced by chloroquine (CQ), an anti-malaria drug
with generalized pruritus (Ajayi et al., 1989). By contrast,
U-50,488 had no effect on histamine-induced scratching
(Figure 1A). Consistently, U-50,488 markedly reduced i.t. GIS,
whereas scratching behavior elicited by neuromedin B (NMB),
a bombesin-related peptide, which is involved in histaminergic
itch (Wan et al., 2017; Zhao et al., 2014b), was not affected
(Figure 1A). The attenuated effect of U-50,488 on GIS and CQ
scratching was absent in Oprk1/mice (Figure S1A), indicating
that U-50,488 reduced scratching via a KOR-specific manner.
There is no difference in scratching behavior induced by GRP
or CQ inmale versus femalemice (data not shown). Furthermore,
we observed a significant decrease in CQ-induced scratching
after i.t. injection of U-50,488 in female mice (Figure S1B), sug-
gesting a lack of sexual dimorphic properties in itch transmission
(Chakrabarti et al., 2010). Finally, we examined the effect of spi-
nal KOR activation on GRPR-dependent chronic itch models
(Zhao et al., 2013). i.t. injection of U-50,488 significantly reduced
spontaneous scratching in BRAFNav1.8 mice, a genetic model for
chronic itch (Figure 1B). U-50,488 also attenuated chronic itchinduced by 2,4-dinitrofluorobenzene (DNFB), a model for allergic
contact dermatitis (ACD), and in mice with dry skin itch induced
by an acetone-ether-water (AEW) treatment (Zhao et al., 2013;
Figures 1C and 1D). These observations demonstrate that spinal
KOR activation inhibits GRPR-dependent acute and chronic
itch.
KOR Inhibits GRPR in a Cell-Autonomous Manner
The finding that KOR activation inhibited GIS prompted us to
examine whether KOR inhibits GIS indirectly through inhibitory
neural circuits or directly in GRPR neurons, which are primarily
excitatory interneurons (Wang et al., 2013). To differentiate be-
tween these two possibilities, we first examined whether KOR
and GRPR are co-expressed in the spinal cord using dual-
labeled RNAscope in situ hybridization (ISH) (Wang et al.,
2012). Oprk1 mRNA was detected in 50% (104/205) of Grpr
neurons in the superficial dorsal horn (Figures 1E and 1F).
The co-expression of KOR and GRPR raised the possibility
that KOR activation may cross-inhibit GRPR in a cell-autono-
mous manner rather than through activation of inhibitory neural
circuits. GRPR transduces itch via the PLCb/IP3/Ca
2+ signaling
pathway (Liu et al., 2011; Zhao et al., 2014a). To examine this,
the dorsal horn of the spinal cord was dissected and dissociated
and neurons were cultured for calcium imaging (Figure 2A; Video
S1). To determine whether U-50,488 inhibits GRP-induced,
GRPR-mediated intracellular Ca2+ mobilization, a two-step pro-
tocol was employed, whereby dissociated dorsal horn GRPR+
neurons can be identified by an application of GRP (20 nM)
and then re-sensitized after a 30-minwash-out period (Figure 2C;
Table S1; Zhao et al., 2014a). The ratio of the second GRP-
induced response to the first responsewas used for quantitation,
thereby avoiding inconsistencies that may result from GRPR+
neuronal heterogeneity. U-50,488 (up to 20 mM) alone did not
induce Ca2+ responses in GRPR+ neurons (data not shown).
However, incubation of U-50,488 (10 mM) attenuated Ca2+ re-
sponses of GRPR+ neurons to GRP (Figures 2B, 2D, and 2F;
Video S2), and this inhibitory effect was reversed by norbinaltor-
phimine (norBNI), a selective KOR antagonist (Portoghese et al.,
1987; Figures 2E and 2F). About 42%of GRPR+ neurons showed
complete inhibition (52/124) by KOR activation, 26% showed
partial inhibition (32/124), and 32% were resistant to U-50,488
application (40/124; Table S2). The finding that the percentage
of non-responders was slightly lower than Grpr+/Oprk1 neu-
rons, as observed by RNAscope ISH (Figures 1E and 1F), could
be due to several factors, such as younger age of mice used for
calcium imaging study and/or different sensitivities associated
with each approach. CQ itch is significantly reduced, but not
abolished, in Grpr KO mice (Sun and Chen, 2007), suggesting
the involvement of a GRPR-independent pathway. To test
whether U-50,488 may inhibit CQ itch via GRPR-independent
pathway, we examined its effect on CQ itch using Grpr KO
mice and found that i.t. U-50,488 did not further reduce CQ-
induced scratching (Figure S2A). This result suggests that spinal
KOR activation inhibits CQ itch predominantly via GRPR-cell-
autonomous mechanism.
Next, we investigated whether KOR activation inhibits GRPR
signaling via the canonical opioid-mediated Gai signaling
pathway (Al-Hasani and Bruchas, 2011). Unexpectedly,Cell Reports 23, 866–877, April 17, 2018 867
Figure 1. Intrathecal Administration of U-50,488 Attenuates Nonhistaminergic Itch
(A) 10-min pre-injection of U-50,488 (10 nmol) significantly reduced scratching induced by CQ (200 mg intradermal [i.d.]) and GRP (0.3 nmol i.t.), but not Hist
(200 mg i.d.) and NMB (1 nmol i.t.; *p < 0.05; ***p < 0.001; Student’s unpaired t test; n = 6–11).
(B–D) Reduced spontaneous scratching in (B) BRAFNav1.8, (C) ACD, and (D) dry-skin mice after U-50,488 injection (*p < 0.05; ***p < 0.001; Student’s paired t test;
n = 7–9).
(E) Representative images of RNAscope in situ hybridization of Grpr (green) and Oprk1 (red) mRNA expression in superficial dorsal horn of transverse lumbar
sections. Arrows indicate double-stained neurons. Blue represents DAPI nucleic acid stain (scale bar, 20 mm).
(F) Venn diagram showing the overlap in expression of Grpr and Oprk1 in dorsal horn neurons (n = 20 lumbar sections from 3 mice). Data are represented as
mean ± SEM.
See also Figures S1 and S2.pertussis toxin (PTX) (200 ng/mL), a Gai inhibitor, did not block
the inhibitory effect of U-50,488 (Figure 2G), suggesting that a
Gai-independent pathway is involved in spinal KOR activation-
mediated itch inhibition. Of the 23 GRPR neurons treated with
PTX, GRP-induced calcium responses in 16/23 (70%) were
completely inhibited by U-50,488, 2/23 (9%) showed partial inhi-
bition, whereas 5/23 (21%)were resistant to U-50,488 treatment.
As expected, PTX reversed U-50,488-mediated inhibition of cy-
clic AMP (cAMP) synthesis in HEK293 cells (Figure S3A). To test
whether KOR may differentially couple to Gas in GRPR-KOR868 Cell Reports 23, 866–877, April 17, 2018cells, we measured cAMP accumulation and found that neither
U-50,488, GRP, nor their co-application induced cAMP accumu-
lation (Figure S3B), implying that it is unlikely that a Gas-depen-
dent pathway is involved in KOR-GRPR cross-signaling.
According to the canonical pathway, activation of KOR re-
cruits G-protein-coupled receptor kinases (GRK). Arrestin will
then bind to the phosphorylated KOR, resulting in acute
desensitization (Bruchas and Chavkin, 2010). In contrast,
U-50,488-mediated desensitization lasts for at least two days
in mice (Figure S1C). Furthermore, U-50,488 attenuated GIS
Figure 2. Activation of KOR Inhibits GRPR Ca2+ Signaling in Dorsal Horn Neurons
(A) Schematic showing dissection of the spinal cord, seeding, and culture of dissociated dorsal horn neurons.
(B) Ratiometric fluorescence images of dissociated GRPR neurons showing changes in calcium after adding 20 nMGRP (62–124 s). After a wash-out period, a 2-
min pretreatment with 10 mM U-50,488 inhibited GRP-induced Ca2+ responses in GRPR neurons (1,880–1,940 s).
(C) Representative traces showing that GRP-induced calcium responses completely recovered after a 30-min wash-out period.
(D) U-50,488 inhibited GRP-induced Ca2+ responses in dissociated dorsal horn neurons.
(E) 10-min pretreatment with 10 mM norBNI blocked the U-50,488 inhibitory effect on GRP-induced Ca2+ responses.
(F) Quantified data comparing peak intracellular concentration evoked by GRP after pretreatment with U-50,488 (red) or norBNI+U-50,488 (purple; ***p < 0.001;
one way ANOVA followed by Tukey’s multiple comparison test; n = 11–27).
(G) PTX (200 ng/mL) had no effect on U-50,488 inhibitory effect on GRP-induced Ca2+ responses (**p < 0.01; NS, not significant; one way ANOVA followed by
Tukey’s multiple comparison test; n = 26–49).
Data are represented as mean ± SEM. See also Figures S2 and S3.in Arrb2/ mice (Figure S3C), consistent with previous studies
(Bohn et al., 2000; Morgenweck et al., 2015). Although we
cannot completely exclude the involvement of arrestinsignaling, due to possible genetic compensation in Arrb2/
mice, the long-lasting effect of KOR-mediated inhibitory action
on itch transmission supports the notion that KOR activationCell Reports 23, 866–877, April 17, 2018 869
Figure 3. PKC Inhibition in the Spinal Cord
Blocks KOR-Activation-Induced Attenua-
tion of Itch
(A) Pre-injection of PMA (1 nmol i.t.) significantly
reduced scratching induced by GRP and CQ (**p <
0.01; ***p<0.001;Student’sunpaired t test; n=6–8).
(B) BIM (40 pmol i.t.), blocked U-50,488 inhibitory
effect on GRP-induced scratching (*p < 0.05; **p <
0.01; one-way ANOVA followed by Tukey’smultiple
comparison test; n = 9–12).
(C) PMA (1 nmol) inhibited spontaneous scratching
in BRAFNav1.8, ACD, anddry-skinmice (***p < 0.001;
Student’s paired t test; n = 7–9).
(D and E) Representative traces (D) and quantified
data (E) show that PMA (1mM) inhibitsGRP-induced
Ca2+ responses in dissociated GRPR neurons
(***p < 0.001; Student’s unpaired t test; n = 12). The
inhibitory effect was no further reduced by co-
application of PMA (1 mM) and U-50,488 (10 mM;
***p < 0.001; Student’s unpaired t test; n = 15).
(F and G) BIM (5 mM) blocked U-50,488 inhibitory
effect on GRP-induced Ca2+ responses (***p <
0.001; Student’s unpaired t test; n = 43–65).
Data are represented as mean ± SEM.attenuates itch through b-arrestin2 signaling-independent
pathway.
Spinal KORActivation Inhibits GRPRFunction via a PKC-
Dependent Mechanism
Previous in vitro studies show that GRPR is a substrate of
PKC that phosphorylates and desensitizes GRPR (Ally et al.,
2003). To explore the possibility that PKC activation inhibits
itch, scratching behavior was examined in mice pre-injected
with i.t. phorbol myristate acetate (PMA), a PKC activator
(Way et al., 2000), which markedly attenuated CQ-induced
scratching and GIS, mimicking the U-50,488 effect (Figure 3A).
Interestingly, bisindolymaleimide (BIM), a selective inhibitor for
PKCa, b1, b2, g, d, and ε isoforms (Toullec et al., 1991),
blocked the effect of U-50,488 on GIS (Figure 3B). Further-
more, PMA completely blocked spontaneous scratching
behavior of BRAFNav1.8 mice, ACD, and dry skin chronic itch
mouse models (Figure 3C). These findings raised a possibility
that KOR activation suppresses itch via PKC-mediated inhibi-
tion of GRPR function.
Next, we examined whether PKC activation could reduce
GRP-induced Ca2+ responses in GRPR+ neurons by applying
PMA. Consistent with behavioral studies, PMA significantly
attenuated GRP-induced Ca2+ responses (Figures 3D870 Cell Reports 23, 866–877, April 17, 2018and 3E). Co-application of PMA and
U-50,488 did not further reduce GRP-
induced Ca2+ responses, suggesting
that KOR activation attenuates GRPR
signaling via PKC (Figures 3D and 3E).
Moreover, pre-incubation with BIM
(5 mM) blocked the inhibitory effect of
U-50,488 on Ca2+ responses of GRPR+
neurons (Figures 3F and 3G). These ob-
servations support the notion that KORactivation attenuates itch transmission via PKC-mediated inhi-
bition of spinal GRPR function.
Activation of KOR Induces GRPR Phosphorylation via
PKC
Whole-cell phosphorylation assays were performed to further
elucidate the role of PKC in KOR-activation-induced inhibition
of GRPR signaling. In HEK293 cells expressing FLAG-KOR and
Myc-GRPR, GRPR phosphorylation increased 13-fold after a
2-min incubation in U-50,488 (10 mM; Figures 4A, 4B, and
S7A). Consistent with behavior and calcium-imaging results,
PKC inhibition by BIM (5 mM) blocked KOR-activation-induced
GRPR phosphorylation (Figures 4C and S7B). Rapid GRPR
phosphorylation was also observed within 2 min after treatment
with PMA (1 mM) and decreased after 15 min (Figures 4D and
S7C), in accordance with previous findings (Ally et al., 2003).
Phosphorylation assays showed that U-50,488-mediated KOR
activation induces rapid and robust, GRP-independent phos-
phorylation of GRPR, which may cause desensitization of
GRPR activity.
KOR Activation Attenuates Itch via PKCd
The PKC family consists of a variety of isoforms that can be clas-
sified into three sub-families: conventional (a, b1, b2, and g; Ca2+
Figure 4. Activation of KOR Induces GRPR
Phosphorylation via PKC
(A and B) Western blots (A) and quantified data (B)
showing that U-50,488 induced robust GRPR
phosphorylation after 2 min in HEK293 cells ex-
pressing KOR and GRPR (**p < 0.01 Student’s
paired t test; n = 4).
(C) BIM (5 mM) blocked U-50,488-induced phos-
phorylation of GRPR (n = 4).
(D) Time course analysis of PMA (1 mM)-induced
GRPR phosphorylation in HEK293 cells.
Data are represented as mean ± SEM. See also
Figure S7.and diacylglycerol [DAG] dependent); novel (d, ε, h, and q; DAG
dependent); and atypical (z and I/l; Nishizuka, 1995; Steinberg,
2008). Given that U-50,488 failed to induce Ca2+ responses in
GRPR neurons, we postulated that Ca2+-independent PKC iso-
forms (PKCd or ε) may be involved in mediating KOR-dependent
PKC activation. To identify the PKC isoform involved, we per-
formed spinal PKC-isoform-specific small interfering RNA
(siRNA) knockdown studies (Liu et al., 2011). Remarkably, siRNA
knockdown of Prkcd not only blocked U-50,488 inhibition of GIS
(Figure 5A) but also enhanced CQ-induced itch, even in the pres-
ence of U-50,488 (Figure 5B). Treatment of control siRNA did not
affect U-50,488 inhibitory effect on GIS and CQ itch (Figures S4A
and S4B). qRT-PCR of the lumbar spinal cord confirmed specific
knockdown of Prkcd, but not Prkca (Figure 5C). Consistently,
U-50,488 lost effect on GRP-induced calcium responses of
dorsal horn neurons isolated from Prkcd/ mice (Figure S5B).
We also performed siRNA knockdown of Prkca. However,
U-50,488 attenuated CQ-induced itch after siRNA knockdown
ofPrkca, suggesting that PKCa does notmediate KOR activation
inhibition of itch (Figures S4C and S4D).
Next, we examined the role of PKCd in KOR-activation-medi-
ated itch inhibition using Prkcd/mice and their wild-type (WT)
littermates (Leitges et al., 2001) and did not find differences in
GIS between Prkcd/ and WT littermates. As predicted, the
inhibitory effect of U-50,488 on GIS is lost in Prkcd/mice rela-
tive to their WT littermates (Figure 5D). To examine whether
PKCd is co-expressed with GRPR in the superficial dorsal
horn, we generated a GrpriCre/Ai9 reporter mouse line by
crossingGrpriCre mice with a tdTomato Ai9 line. Double immuno-
histochemistry (IHC) studies were conducted, and PKCdwas de-
tected inGrpriCre-tdTomato+ neurons (arrows indicate overlap in
expression; Figure 5E). Further, we labeled spinal GRPR neurons
with enhanced yellow fluorescent protein (eYFP) by injection of
AAV5-Ef1a-DIO-eYFP virus into the dorsal spinal cord ofGrpriCre
mice. Consistently, we detected numerous PKCd in GrpriCre;
AAV-DIO-eYFP neurons (Figures 5F and S5A).KOR Activation Induces PKCd Translocation to the
Plasma Membrane
To further evaluate the role of PKCd in KOR-activation-induced
inhibition of GRPR signaling, we examined PKC translocationfrom the cytosol to the plasma membrane, a hallmark of PKC
activation (Mochly-Rosen et al., 1990). Using GFP-tagged
PKC, the dynamics of PKC translocation in response to different
stimuli can be monitored in live cells and in real time (Oancea
et al., 1998; Wang et al., 1999). HEK293 cells expressing KOR
and GRPR were transfected with PKCd-EGFP or PKCa-EGFP.
Confocal live-cell imaging was then performed to characterize
spatiotemporal properties of PKCd-EGFP or PKCa-EGFP after
application of U-50,488 or PMA. PKCd and PKCa were present
in the cytosol without stimulation (Figure 6A; 0 min). Application
of U-50,488 (10 mM) prompted translocation of PKCd, but not
PKCa, to the cell membrane. PKCd-EGFP translocation from
the cytosol to the plasma membrane was apparent as early as
5 min and reached a maximum after 30 min of incubation in
U-50,488 (Figure 6A; Video S3). After U-50,488 treatment, trans-
location to the plasma membrane increased significantly (from
15% ± 4% to 62% ± 8%; Figure 6B). As expected, direct activa-
tion of PKC with PMA (100 nM) induced translocation of both
PKCd-EGFP and PKCa-EGFP from the cytosol to the membrane
(Figures 6C and 6D; Video S4).
To evaluate that the U-50,488-induced PKCd translocation
observed in HEK293 cells mimics events in vivo, the fraction of
PKCd-positive dorsal horn neurons was quantified 30 min after
i.t. injection of U-50,488 in mice. We found that the fraction of
dorsal horn neuronswith plasma-membrane-bound PKCd nearly
doubled after U-50,488 injection (from 40% ± 1% to 73% ± 2%;
Figures 6E–6G). This confirmed that KOR activation stimulates
PKCd activity manifested by its translocation to the plasma
membrane, which subsequently phosphorylates and desensi-
tizes GRPR signaling.KOR Activation Stimulates PKCd via PLC
To elucidate the mechanism by which KOR activation stimulates
PKCd, we tested a myriad of inhibitors on U-50,488-induced
PKCd translocation in HEK293 cells expressing KOR and
GRPR. Pre-incubation of U73122 (10 mM), a PLC inhibitor, for
10 min blocked U-50,488-induced PKCd-EGFP translocation
to the plasma membrane. In contrast, U-50,488 treatment
increased the membrane translocation of PKCd-EGFP from
12% ± 4% to 64% ± 5% in the presence of U73343 (10 mM),
an inactive analog of U73122 (Figures 7A and 7B). Furthermore,Cell Reports 23, 866–877, April 17, 2018 871
Figure 5. U-50,488 Attenuates Itch via PKCd
(A and B) U-50,488 failed to block scratching
induced by (A) GRP (0.06 nmol i.t.) and (B) CQ
(100 mg i.d.) inPrkcd siRNA-treatedmice (*p < 0.05;
one way ANOVA followed by Tukey’s multiple
comparison test; n = 7).
(C) qRT-PCR showed that the level of spinal Prkcd
mRNA was significantly reduced by Prkcd siRNA
injection, whereas the Prkca mRNA level was not
affected (*p < 0.05; Student’s unpaired t test; n = 4).
(D) U-50,488 failed to block scratching induced by
GRP (0.3 nmol i.t.) in Prkcd/mice (*p < 0.05; **p <
0.01; Student’s unpaired and paired t test; basal
relative to U-50; n = 7–9).
(E) Double IHC of tdTomato (red) and PKCd (green)
shows co-expression of GRPR and PKCd in su-
perficial dorsal horn neurons.
(F) Double IHC of PKCd (purple) and eYFP (green)
shows co-expression of GRPR and PKCd in
superficial dorsal horn neurons of Grpr-iCre mice
injected with AAV-DIO-eYFP. Arrows indicate dou-
ble-stained cells. The scale bar represents 10 mm.
Data are represented as mean ± SEM. See also
Figure S5.U-50,488 treatment increased the translocation of PKCd-EGFP
from 11% ± 2% to 47% ± 5% and 15% ± 3% to 70% ± 9% after
a prior pre-incubation in gallein (100 mM), a Gbg inhibitor, and PTX
(200 ng/mL), respectively (Figures 7C and 7D), suggesting that
PLC mediates PKCd activation by KOR in a Gbg- and Gai-inde-
pendent process. Whole-cell phosphorylation assays were
also used to show that KOR activation induces GRPR phosphor-
ylation via PLC. U73122, but not U73343, blocked GRPR phos-
phorylation (Figures 7E, 7F, and S7D). Together, these results
suggest that KOR activation stimulates PLC, resulting in the
translocation of PKCd from the cytosol to the plasmamembrane,
where it phosphorylates GRPR (Figure 7G).
To investigate whether this pathway is similarly engaged by
other KOR agonists, we tested butorphanol, a mixed KOR
agonist/MOR antagonist (Abeliovich et al., 1993), which has
been used to treat various types of intractable pruritus in human
studies (Dawn and Yosipovitch, 2006; Dunteman et al., 1996).
We found that i.t. injection of butorphanol (2 nmol) significantly
reduced CQ-induced scratching behaviors in WT, but not in
Oprk1/mice (Figure S2B), suggesting that butorphanol inhibits
CQ itch via a KOR-dependent mechanism. Furthermore, i.t. in-872 Cell Reports 23, 866–877, April 17, 2018jection of butorphanol (2 nmol) did not
further reduce CQ-induced scratching in
Grpr KO mice (Figure S2C). Consistently,
butorphanol also lost effect in Prkcd/
mice (Figure S2D). These studies provide
clinically relevant evidence supporting
that spinal KOR-agonists-mediated itch
inhibition is dependent on the KOR-
GRPR cross-talk, but not other mecha-
nisms. In HEK293 cells expressing KOR
and GRPR, butorphanol induced PKCd-
EGFP, but not PKCa-EGFP, translocation
from the cytosol to the plasma mem-brane, mimicking the U-50,488 effect (Figure S6). Consistent
with U-50,488 and butorphanol results, dynorphin, an endoge-
nous ligand for KOR (Chavkin et al., 1982), also attenuated
CQ-induced itch (Figure S2E). However, mice lacking dynorphin
(Pdyn/) exhibited normal acute and chronic itch (Figures S2F
and S2G). These data demonstrate that spinal KOR activation
by different agonists suppresses itch transmission via PLC-
PKCd pathway and endogenous dynorphin is not required for
itch modulation under either normal physiological or chronic
itch conditions.
DISCUSSION
Using a multidisciplinary and spinal-cord-specific approach, we
show that a Ca2+-independent KOR-PLC-PKCd-GRPR pathway
is activated in response to KOR agonists, resulting in an attenu-
ation of GRPR function, which is required for development of
chronic itch in mice (Sun and Chen, 2007; Zhao et al., 2013).
Consistent with previous findings showing that GRPR is mini-
mally required for histaminergic itch (Akiyama et al., 2014; Sun
et al., 2009; Zhao et al., 2013), we show that spinal KOR
Figure 6. KOR Activation Induces Translo-
cation of PKCd, but Not PKCa, to the Plasma
Membrane
(A) HEK293 cells expressing KOR/GRPR trans-
fected with PKCd-EGFP (upper row) and
PKCa-EGFP (lower row) were incubated in
10 mM U-50,488. Confocal images taken at
indicated time points showed that U-50,488
induced the translocation of PKCd-EGFP, but not
PKCa-EGFP, to the plasma membrane (scale
bar, 20 mm).
(B) Percentage of PKCd-EGFP and PKCa-EGFP
translocation to the plasma membrane in
response to U-50,488 (**p < 0.01; Student’s
paired t test; n = 3–4 cells per experiment).
(C) 100 nM PMA incubation induced the trans-
location of both PKCd-EGFP and PKCa-EGFP to
the plasma membrane.
(D) Percentage of PKCd-EGFP and PKCa-EGFP
translocation to the plasma membrane in res-
ponse to PMA (*p < 0.05; **p < 0.01; Student’s
paired t test; n = 3–4 cells per experiment).
(E) IHC image shows that PKCd (red) is mostly
distributed in the cytosol of superficial dorsal
horn neurons of control mouse (upper row). After
U-50,488 injection, PKCd translocates to the
plasma membrane (lower row). Arrows show
neurons with PKCd distributed at the plasma
membrane (scale bar, 20 mm).
(F) High-power images of the boxed regions in
(E; scale bar, 5 mm; blue, NeuN).
(G) Percentage of PKCd translocation to the plasma membrane after U-50,488 injection relative to control in dorsal horn neurons (***p < 0.001; Student’s
unpaired t test; n = 18 lumbar sections from 3 mice).
Data are represented as mean ± SEM. See also Figure S6.activation does not impact histaminergic itch, including NMB-
mediated scratching behavior (Wan et al., 2017; Zhao et al.,
2014b). Our data suggest that the anti-histaminergic itch effect
elicited by systemic KOR agonists is likely attributable to periph-
eral KOR (Bigliardi-Qi et al., 2007; Chuang et al., 1995; Suzuki
et al., 2001; Togashi et al., 2002). Taken together, these findings
illustrate a spinal mechanism by which KOR agonists attenuate
itch transmission.
Spinal KOR activation reduces itch transmission by inhibiting
the function of GRPR in a cell-autonomous manner in KOR-
GRPR neurons. In addition to GRPR excitatory neurons, KOR
is also expressed in non-GRPR GABAergic neurons in the spi-
nal cord (Xu et al., 2004). Activation of KOR in non-GRPR neu-
rons by KOR agonists could induce thermal analgesia (Naka-
zawa et al., 1990; Porreca et al., 1984; Xu et al., 2004), likely
via the Gai signaling pathway (Al-Hasani and Bruchas, 2011;
Grudt and Williams, 1993; Randic et al., 1995). Because of
itch and pain antagonism and their distinct neuronal outputs,
it is unlikely that inhibition of non-GRPR KOR neurons in the
spinal cord would contribute to itch inhibition. Importantly,
KOR-agonist-induced anti-itch effect is lost in Grpr KO mice,
suggesting that GRPR is required for mediating anti-itch ef-
fects. The remaining KOR-agonist-resistant scratching effect
induced by CQ in Grpr KO mice is likely mediated by glutama-
tergic transmission in Grpr/ neurons that are also required for
histaminergic transmission (Akiyama et al., 2014; Wan et al.,
2017). Taken together, depending on GRPR and neurotrans-mitter expression, activation of KOR neurons in the spinal
cord gives rise to two distinct behavioral outputs: GABAergic
KOR neurons compute anti-nociceptive output, whereas excit-
atory KOR-GRPR neurons convey anti-pruriceptive information
(Figure 7H). The dual role of KOR is reminiscent of MOR1 and
5HT1A, which is predominantly implicated in anti-nociceptive
signaling, with only a small percentage communicating with
GRPR, in contrast to KOR-GRPR, to induce or facilitate itch
(Liu et al., 2011; Zhao et al., 2014a). Thus, depending on ago-
nists and type of GPCRs, GRPR neurons could serve as a gate
to control the output of itch information.
The observation that PTX fails to reverse the effect of U-50,488
demonstrates that KOR signaling via a non-canonic Gai-inde-
pendent pathway, is specific to KOR-GRPR excitatory neurons.
The finding that KOR-activation-mediated signal transduction is
independent of Gbg protein as well as Gas protein suggests that
KOR may activate PLC independent of G protein. How could
KOR activate PKCd, but not PLCb, which acts downstream of
GRPR (Liu et al., 2011), in GRPR neurons? It is possible that
KOR activation selectively recruits PKCd to phosphorylate
GRPR, thereby dampening PLCb signaling via a competitive
manner (Figure 7G). It is also likely that the presence of a
GRPR-KOR heteromeric complex switches the downstream
signaling kinase cascade of canonic KOR pathway to occlude
PLCb activation.
One remarkable finding is that Ca2+-independent PKCd acti-
vation via membrane translocation provides a major mechanismCell Reports 23, 866–877, April 17, 2018 873
Figure 7. PLC Mediates KOR-Activation-
Induced Translocation of PKCd to the
Plasma Membrane
(A–D) Confocal images (A and C) and quantified
data (B and D) showing U-50,488 induced trans-
location of PKCd-eGFP from the cytosol to the
plasma membrane was blocked by 10 mMU73122
(PLC inhibitor) (A and B). U73343 (inactive analog
of U73122) (A and B), 100 mMgallein (Gbg inhibitor),
and 200 ng/mL PTX (Gai inhibitor; C and D) had no
effect on U-50,488-induced translocation of
PKCd-eGFP (n = 3–4 cells per experiment; *p <
0.05; Student’s paired t test in B; one-way ANOVA
followed by Dunnett’s multiple comparison test).
(E and F) Western blots (E) and quantified data (F)
showing that U-50,488-induced GRPR phosphor-
ylation is blocked by U73122, but not U73343.
Data are represented as mean ± SEM. See also
Figure S5.
(G) Schematic showing signaling events by which
KOR activation results in GRPR desensitization.
KOR activation by U-50,488 stimulates PLC to
hydrolyze PIP2 into DAG, which in turn induces
PKCd translocation from the cytosol to the plasma
membrane, resulting in GRPR phosphorylation
and desensitization.
(H) Schematic illustrates concurrent activation of
two distinct subpopulations of dorsal horn in-
terneurons by U-50,488: activation of KOR neu-
rons without GRPR mediates anti-nociceptive
output, whereas activation of KOR/GRPR neurons
inhibits itch.by which GRPR is phosphorylated and desensitized. Impor-
tantly, behavioral studies indicate that PKCd-mediated desensi-
tization of GRPR is long lasting. Previous in vitro studies sug-
gested that the classic GRPR-PLC-IP3 Ca
2+ signaling activates
kinases other than PKC (Kroog et al., 1995), and GRPR
agonist-induced Ca2+-dependent desensitization is transient
and lasts less than 2 min (Zhao et al., 2014a). It is possible that
distinct phosphorylation sites at the C-terminal domain of
GRPR may contribute to the duration of desensitization (Ally
et al., 2003). Whether PKCd desensitizes agonist-unoccupied
GRPR via direct phosphorylation or indirectly via other kinases
awaits further studies (Kelly et al., 2008). Direct examination of
spinal GRPR phosphorylation levels after KOR activation re-
quires an antibody that can specifically detect phosphorylated
GRPR in vivo, which contains multiple potential phosphorylation
sites on its C terminus (Ally et al., 2003). Several lines of evidence874 Cell Reports 23, 866–877, April 17, 2018fail to support the view that the endoge-
nous dynorphin is an important modulator
of itch transmission (Kardon et al., 2014):
first, consistent with previous studies us-
ing either Pdyn KOmice or ablation of spi-
nal Dyn+ neurons (Duan et al., 2014; Kar-
don et al., 2014), Pdyn KO mice showed
normal acute and chronic itch behaviors.
Second, KOR agonists attenuate GRPR
function via a long-lasting phosphoryla-
tion rather than acute desensitization pro-cess, the former of which rarely occurs under normal physiolog-
ical condition. These observations are in support of the notion
that KOR-GRPR cross-signaling induced by exogenous KOR
agonists reflects an artificial process. While there is no evidence
that the endogenous dynorphin modulates itch in normal physi-
ological context, the possibility that a dramatic down-regulation
of Pdyn in chronic itch condition (data not shown) may suggest
an attenuation of inhibitory circuit cannot be excluded.
In summary, we demonstrate a non-canonical opioid signaling
mechanism by which GRPR activity is attenuated by KOR-medi-
ated cross-signaling in the spinal cord of mice. The finding of the
inhibitory effect of KOR activation and its downstream signaling
components on distinct types of chronic itch (BRAFNav1.8, ACD,
and AEW) suggests a possibility for a broader application of
KOR-GRPR-based anti-itch strategy to the treatment of chronic
itch with various etiologies.
EXPERIMENTAL PROCEDURES
Animals
Behavioral tests were carried out on C57BL/6J,Oprk1/ (Hough et al., 2000),
Grpr KO (Hampton et al., 1998), BRAFNav1.8 (Zhao et al., 2013), GrpriCre, Ai9
(MMRRC), Arrb2/ (Bohn et al., 1999), and Prkcd/ (Leitges et al., 2001)
malemice and their WT littermates unless indicated otherwise. All experiments
conform to guidelines set by the NIH and the International Association for the
Study of Pain and were reviewed and approved by the Animal Studies Com-
mittee at Washington University School of Medicine.
Itch Behavior
Mice were individually put into observation boxes and videotaped. The
videos were played back on a computer and quantified by an observer
who was blinded to the treatment or mice genotype. A scratch is defined
as a bout of scratching that occurs after the mouse lifts its hind paw to the
moment the hind paw is returned to the ground or mouth (Sun and Chen,
2007). For the dry-skin model, mice were painted twice daily with a mixture
of acetone and diethyl ether (1:1) followed by water. Scratching behavior
directed at the neck was counted in the morning before treatment (Miyamoto
et al., 2002; Zhao et al., 2013). For ACD model, mice were sensitized by
applying 100 mL of 0.15% DNFB on abdominal skin. One week later, mice
were challenged by nape application of 50 mL of 0.15% DNFB every 2 or
3 days. Scratching responses were measured 24 hr after applying DNFB
(Zhao et al., 2013).
RNAscope In Situ Hybridization and Immunohistochemistry
RNAscope ISH and IHC staining were performed as described (Wang et al.,
2012; Zhao et al., 2014a). Spinal sections were processed according to the
manufacturer’s instructions in the RNAscope Fluorescent Multiplex Assay v2
manual for fixed frozen tissue (Advanced Cell Diagnostics).
siRNA Studies
Prkcd siRNA (Sigma) was delivered to the lumbar region of the spinal cord via
i.t. injection as described (Liu et al., 2011; Zhao et al., 2014a). Mice were in-
jected twice daily for 3 consecutive days, and behavior was performed 24 hr
after the last injection.
Dissociation of Dorsal Horn Neurons and Calcium Imaging
Primary culture of spinal dorsal horn neurons was prepared from 5- to 7-day-
old C57BL/6J mice and seeded onto 12-mm coverslips coated with poly-D-
lysine. Calcium imaging was performed 3–5 days after seeding as described
previously (Zhao et al., 2014a).
Whole-Cell Phosphorylation Assay
HEK293 cells expressing FLAG-KOR andMyc-GRPRwere incubated in 10 mM
U-50,488 or 1 mM PMA at 37C and lysed as described (Liu et al., 2011). Pro-
teins were incubated with mouse anti-Myc antibody (Sigma) overnight. The
complex was precipitated, resolved on polyacrylamide gels, and transferred
to polyvinylidene fluoride (PVDF) membranes (Millipore). Proteins were de-
tected by immunoblotting with mouse anti-phosphoserine antibody (1:2,500;
Sigma) overnight, and the blot was developed by enhanced chemilumines-
cence (Thermo Scientific).
PKC Translocation Assay
KOR-GRPR HEK293 cells, transiently expressing PKCd-EGFP or PKCa-EGFP
(kindly provided by Dr. Peter M. Blumbergtaken) were seeded in 29-mm
glass bottom dishes (In Vitro Scientific). After 24 hr, the subcellular distribution
of EGFP-fused protein was analyzed on a Leica TCS SPE confocal
microscope.
Statistical Analysis
Statistical comparisons were performed with Graphpad Prism 7. Groups
were considered significantly different if p < 0.05. Results are presented as
the mean ± SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, two tables, and four videos and can be foundwith this article on-
line at https://doi.org/10.1016/j.celrep.2018.03.087.
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